



SEMPERIT GROUP Q1 2023 INVESTOR PRESENTATION

Karl Haider, CEO

Helmut Sorger, CFO

10 May 2023



Key Highlights (p.2)

Operational Performance (p.5)

Financial Performance & Strategy (p.13)

Outlook (p.24)

Appendix (p.28)



Strategic and operational highlights Q1 2023



Industrial Sector stable with slight increases – against the backdrop of lower order intake and higher cost levels – effects of inventory adjustments in the markets not yet visible in the results



Medical business under responsible stewardship before sale completed to new owner



Acquisition of RICO, a leading global specialist in the production of liquid silicone-based solutions, signed on April 17



New structured financing – two individual agreements totaling up to EUR 360m




Base dividend of EUR 1.50 per share and conditional special dividend of EUR 3.00 per share – with the latter to be paid after closing of Sempermed sale





Rico Group: Excellent strategic fit for Semperit





Agenda

Key Highlights (p.2)

Operational Performance (p.5)

Financial Performance & Strategy (p.13)


Outlook (p.24)

Appendix (p.28)




Industrial Sector: Stable results with revenues and EBITDA slightly above PY

Revenues in EUR m
Q1'21 – Q1'23



Quarterly development of EBITDA (EURm) and EBITDA margin (%)




- Industrial Sector performance stable and still positive despite lower sales volumes in all except Sempertrans
- Impact of customer inventory adjustments leading to lower sales volumes in hydraulic hoses (Semperflex) and ongoing difficult market environment in the construction industry (Semperseal)
- Capacity adjustments and strict cost management



Detail on Last Twelve Month (LTM) view of the Industrial Sector

LTM development of Revenue (EURm) and EBITDA margin (%)







Semperflex Q1 2023

Customer destocking and lower order intake

Semperflex



Q1 2023 vs. Q1 2022



- Most of Semperflex customers are still faced with high inventories – resulting in lower sales, weaker order intake and reduction in order book
- Sales down by 9% and EBITDA by 15% yoy
- Higher costs of raw materials, transport, energy and personnel yoy in combination with lower sales volumes put margins under pressure








Sempersal Q1 2023

Impact of economic slowdown in construction business


Sempersal



Q1 2023 vs. Q1 2022



- Tight market with a particularly weak demand in construction industry resulted in lower orders
- Top-line growth down 13% yoy due to lower sales volumes despite higher price levels vs. Q1'22
- Higher costs and lower volumes impact margins at EBITDA and EBIT level
- Cost reduction measures started – including rightsizing overhead base







Sempertrans Q1 2023

Tangible turnaround

Sempertrans



Q1 2023 vs. Q1 2022



- Positive developments of project pipeline – Sempertrans offered highly competitive products and services
- Ongoing strong demand from mining industry for steel and textile belts – strong order book
- Tailwinds from European energy crisis
- Sales up by 52% and EBITDA more than 5 times higher yoy
- Higher volumes and price increases offset input costs, resulting in very strong margins





¹ Q4'22 EBITDA: positive net effect of EUR 4.7m from sale of property in connection with factory closure in France in 2018




Semperform Q1 2023

Results impacted by price increases and changed product mix

Semperform



Q1 2023 vs. Q1 2022



- Order book still up on a yoy comparison but slightly down overall due to strong pent-up demand in previous periods
- Ongoing product portfolio clean-up
- Revenues up by 10% due to price levels above Q1'22 and product mix
- EBITDA up by 54% due to product mix and increased profitability offsetting higher input costs







Medical Sector / Sempermed segment Q1 2023

Excess capacity, reduced demand and further inventory clean-up impact volumes

Sempermed



Q1 2023 vs. Q1 2022



- Ongoing destocking burdens demand for both examination and surgical gloves
- High price pressure due to excess capacities especially for examination gloves
- EBITDA benefited from release of provisions (e.g., gas contracts, inventory) but heavily impacted by low prices and higher costs
- Write-up of EUR 1mn in Q1'23
- Responsible stewardship for Sempermed



¹ Q4'22 EBITDA includes transaction costs of EUR 8.4m as a result of the agreed sale of Sempermed



Agenda

Key Highlights (p.2)

Operational Performance (p.5)

Financial Performance & Strategy (p.13)

Outlook (p.24)

Appendix (p.28)



Q1 2023 Financial Highlights



- **Stable top line of continued operations**
- **Results slightly higher despite macro economic headwinds**
- **Margins increasingly under pressure from cost inflation**
- **Positive earnings after tax**



- **Focus on cost control and adjustment of overhead base with a view on**
 - **Digitalisation,**
 - **Efficient processes,**
 - **Streamlining of workflows,**
 - **Empowerment of the organisation**



- **Working capital management remains core of our activities**
- **Positive free cash flow**



- **Financial position stronger than year-end 2022, supported by new financing set-up since March 31**





Two new financing arrangements since 31 March 2023



EUR 250m

General Corporate Purpose Financing

- **EUR 150m** term loan for acquisition of RICO
- **EUR 100m** Revolving Credit Facility

Consortium of six Austrian and international banks

ESG-KPIs agreed:

- **Energy Efficiency**,
- **Incident Rate** and
- **Water Consumption**



















EUR 110m

Lighthouse transaction with Czech export credit agency (**EGAP**)

- **DH5 expansion** and **general corporate purposes**
- **Partial green-loan** eligibility




Overview of key financial KPIs, Q1 2022 vs. Q1 2023 (as reported)

	Q1 2022	Q1 2023	Δ Q1'22/'23
Revenues, in EUR m	 // 181.5	 185.2	↗ 2.0%
EBITDA, in EUR m	 20.3	 20.8	↗ 2.7%
EBITDA margin, in %	 11.2	 11.2	↗ 0,0PP
EBIT, in EUR m	 12.7	 13.2	↗ 4.2%
EBIT margin, in %	 7.0	 7.1	↗ 0.1PP
Earnings after tax, in EUR m	 15.5	 0.4	↘ n.m.
Free Cashflow, in EUR m	 -0.1	 7.1	↘ n.m.
CAPEX, in EUR m	 17.1	 14.5	↘ 15.2%



Revenue: Segment reporting & reconciliation for continued business




% change of each segment / sector refers to 2022 vs. 2021.

¹Sales between continued and discontinued business



Strong performance in Industrial against steep decline in Medical

in EUR m




EBITDA Q1'22	36.5	19.6	2.4	1.3	3.2	13.3	-3.2	
EBITDA Q1'23		16.7	1.6	7.3	5.0	-11.6	-7.3	11.7
margin Q1'23		23.0%	5.0%	17.0%	17.2%	-4.7%	-	5.4%

¹ EUR 0.1 m adjustment refers to transaction cost incurred in Q1 2023



Major drivers of operating performance

in EUR million






Quarterly CAPEX development 2021-2023

- Q1 2023 CAPEX slightly below prior-year level
- Industrial will receive higher CAPEX
- Outlook: FY2023 maintenance CAPEX to remain stable at EUR ~50m and an additional EUR ~50m planned for growth investments (DH5)

CAPEX per segment


in EUR m





Free cash flow development

- Operating cash flow slightly up due to positive impact from working capital management
- Investment cash flow lower than in previous year
- Free Cash Flow at EUR 7.1m




¹ before strategic growth investments



Working Capital overview

Components of Working Capital

in EUR m



Trade Working Capital in % of LTM revenues;


¹ 31. Dec 2022 and March 31 2023 without disposal group Sempermed, all historical values in total



Balance sheet structure and financial profile (contd. operations)

Balance sheet structure

Balance sheet 31/03/2023: EUR 848m
Balance sheet 31/12/2022: EUR 843m



Financial profile as of 31 March 2023

- **Cash and cash equivalents** at EUR 119m – Strong cash position to fend off inflationary impact and supporting recent M&A
- **Corporate Schuldschein loan** at EUR 53m
- **“Net debt” remains net cash** at EUR 66m, Net debt / EBITDA below zero (YE’21: below zero)
- **Equity ratio** of 61.1% (YE’22: 61.5%)
- **New financing** of EUR 360m arranged
- **Dividend:** base dividend of EUR 1.50 per share (paid in May 2023) and conditional additional dividend of EUR 3.00 (to be paid after closing sale of Sempermed)



Agenda

Key Highlights (p.2)

Operational Performance (p.5)

Financial Performance & Strategy (p.13)

Outlook (p.24)

Appendix (p.28)



Management agenda 2023



Operations:

- **Lower order intake in the wake of slowing demand and customer inventory adjustment**
- **Growing price sensitivity and ongoing cost pressure, notably for personnel and possibly for energy and raw materials**
- **Strict cost control, capacity adjustments and lean processes**
- **Focus share of wallet gains**

Strategy:

- **Refinement of industrial elastomer strategy**
- **Important step towards implementation already taken through acquisition of RICO Group, one of the world's leading specialists in liquid-silicone solutions**
- **Sale of medical business signed; responsible stewardship and focus on carve out to ensure a smooth transition**



Outlook 2023 (continued operations)



EBITDA at the lower end of the range of 70–90m EUR confirmed

CAPEX ~ 100 m EUR for 50:50 growth and maintenance



Contact and financial calendar

Investor Relations Semperit

Judit Helenyi, Director Investor Relations

+43 1 79777 - 310

www.semperitgroup.com/en/ir

Am Belvedere 10

1100 Vienna, Austria

Financial Calendar 2023

10.05.2023	Report on Q1 2023
10.08.2023	Half-year financial report 2023
08.11.2023	Report on Q1-3 2023

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



Agenda

Key Highlights (p.2)

Operational Performance (p.5)

Financial Performance & Strategy (p.13)

Outlook (p.24)

Appendix (p.28)



Sectors and Group: Q1 2023 vs Q1 2022

in EUR m	Industrial Sector			Medical Sector			Semperit Group		
	Q1 2023	Q1 2022	%	Q1 2023	Q1 2022	%	Q1 2023	Q1 2022	%
Revenue	176.4	171.0	+3.2%	39.6	106.1	-62.7%	185.2	181.5	+2.0%
EBITDA	30.6	26.4	+15.7%	-11.6	13.3	>100%	20.8	20.3	+2.7%
EBITDA margin	17.3%	15.5%	+1.9 PP	-29.3%	12.6%	-41.9 PP	11.2%	11.2%	+0.1 PP
EBIT	23.7	19.6	+20.6%	-13.5	7.6	>100%	13.2	12.7	+4.2%
EBIT margin	13.4%	11.5%	+1.9 PP	-34.2%	7.2%	-41.4 PP	7.1%	7.0%	+0.1 PP
Earnings after tax from continued operations	-	-	-	-	-	-	8.3	7.3	+13.2%
Earnings after tax from discontinued operations	-	-	-	-	-	-	-7.9	8.2	n/a
Earnings after tax	-	-	-	-	-	-	0.4	15.5	-97.4%
Earnings per share in EUR	-	-	-	-	-	-	0.02	0.75	-96.7%
Additions in tangible and intangible assets	5.0	4.3	+16.4%	0.7	4.5	-84.1%	5.4	10.0	-46.3%
Employees	3,756	3,881	-3.2%	2,681	3,052	-12.2%	6,510	7,007	-7.1%




Semperit Group adj. where applicable


Semperit Group adj. where applicable

in EUR m	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022 adj. ¹⁾	Q4 2022 adj. ²⁾	FY 2022 adj. ²⁾	Q1 2023
Revenue	323.1	337.7	265.3	256.1	1,182.2	277.0	293.6	259.0	228.6	1,058.2	185.2
EBITDA	122.2	125.3	76.8	37.5	361.8	36.5	38.7	10.7	8.3	94.1	20.8
EBITDA margin	37.8%	37.1%	28.9%	14.6%	30.6%	13.2%	13.2%	4.1%	3.6%	8.9%	11.2%
EBIT	110.8	113.8	65.4	25.0	315.0	23.7	24.7	-3.5	-2.6	42.3	13.2
EBIT margin	34.3%	33.7%	24.7%	9.8%	26.6%	8.6%	8.4%	-1.4%	-1.1%	4.0%	7.1%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Q3 2022: adjusted for the negative one-off effect of the impairments in segments Sempermed and Semperseal (Q3 2022: EBIT effect EUR -53.9 million, earnings after tax EUR -53.9 million). ⁵⁾ numbers refer to segment view, as if no separation has taken place; 2022 adjusted for the positive one-off effect of the net proceeds from the sale of property in France in the Sempertrans segment (2022: effect on EBITDA and EBIT: EUR 4.7 million) and for the negative one-off effect of the net impairments in the Sempermed and Semperseal segments (2022: effect on EBIT: EUR -12.9 million) and negative effect of the transaction costs (2022: effect on EBITDA: EUR -8.4 million).



Semperflex and Semperseal (adj. where applicable)

Semperflex (Hoses)

	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022	Q1 2023
in EUR m											
Revenue	54.7	59.7	57.7	68.4	240.5	79.8	93.9	78.5	76.6	328.8	72.6
EBITDA	12.3	13.9	11.2	13.9	51.3	19.6	27.3	21.5	13.9	82.2	16.7
EBITDA margin	22.5%	23.3%	19.3%	20.4%	21.3%	24.5%	29.0%	27.3%	18.1%	25.0%	23.0%
EBIT	9.6	11.1	8.4	11.0	40.0	16.6	24.3	18.5	10.8	70.2	13.6
EBIT margin	17.5%	18.5%	14.5%	16.1%	16.6%	20.8%	25.8%	23.6%	14.1%	21.4%	18.8%

Sempersal (Profiles and Rubber Sheeting) starting in 2020

	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022 adj. ¹⁾	Q4 2022	FY 2022	Q1 2023
in EUR m											
Revenue	28.7	30.3	32.4	29.1	120.5	36.6	38.4	38.3	28.8	142.1	32.0
EBITDA	4.2	2.4	4.1	0.9	11.6	2.4	3.9	3.2	-1.2	8.3	1.6
EBITDA margin	14.7%	7.9%	12.6%	3.0%	9.6%	6.5%	10.1%	8.3%	-4.1%	5.8%	5.0%
EBIT	2.6	0.8	2.5	-0.9	5.1	0.5	2.3	-0.6	-2.9	-0.6	0.0
EBIT margin	9.2%	2.6%	7.7%	-3.1%	4.2%	1.4%	5.9%	-1.4%	-9.9%	-0.4%	0.0%

1) Adjusted for the negative one-off effect of the impairment in the segment Semperseal (Q3 2022: EBIT effect: EUR -2,1 million).



Sempertrans and Semperform (adj. where applicable)

Sempertrans (Conveyor belts)

	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022 adj. ¹⁾	FY 2022 adj. ¹⁾	Q1 2023
in EUR m											
Revenue	26.9	24.2	28.0	25.3	104.5	28.3	41.5	40.0	42.1	151.9	43.0
EBITDA	1.0	0.8	4.7	0.4	6.8	1.3	5.3	3.7	4.7	14.9	7.3
EBITDA margin	3.8%	3.3%	16.7%	1.4%	6.6%	4.5%	12.9%	9.2%	11.2%	9.8%	17.0%
EBIT	0.2	-0.1	3.8	-0.7	3.2	0.3	4.4	2.6	3.6	10.8	6.2
EBIT margin	0.7%	-0.2%	13.6%	-2.9%	3.1%	1.2%	10.5%	6.5%	8.5%	7.1%	14.4%

Semperform (Window and door profiles, Handrails) - after 2020

	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022	Q1 2023
in EUR m											
Revenue	19.8	23.6	23.3	23.9	90.6	26.2	27.5	29.3	29.3	111.1	28.8
EBITDA	3.1	3.6	3.3	2.5	12.4	3.2	5.0	4.1	4.1	15.1	5.0
EBITDA margin	15.4%	15.2%	14.1%	10.3%	13.7%	12.2%	18.3%	13.9%	13.9%	13.6%	17.2%
EBIT	2.1	2.6	2.3	1.4	8.5	2.1	4.0	3.0	3.0	10.8	3.9
EBIT margin	10.8%	11.2%	10.0%	6.0%	9.4%	8.2%	14.4%	10.3%	10.3%	9.7%	13.4%

1) Q4 2022 and 2022: adjusted for the the positive one-off effect of the net proceeds from the sale of property in France in the Sempertrans segment (2022: EBITDA and EBIT effect: EUR -4.7 million).



Sempermed (adj. where applicable)

Sempermed (Gloves)											
	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022 adj. ¹⁾	Q4 2022 adj. ²⁾	FY 2022	Q1 2023
in EUR m											
Revenue	192.9	199.8	124.0	109.4	626.1	106.1	92.3	72.9	-225,4	324.2	39.6
EBITDA	105.3	115.3	56.9	23.7	301.1	13.3	2.3	-19.6	-3,8	-15.4	-11.6
EBITDA margin	54.6%	57.7%	45.9%	21.7%	48.1%	12.6%	2.5%	-26.9%	1,7%	-4.7%	-29.3%
EBIT	100.2	110.3	52.1	18..3	280.9	7.6	-4.7	-78.5	13,9	-36.9	-13.5
EBIT margin	52.0%	55.2%	42.0%	16.7%	44.9%	7.2%	-5.1%	-107.6%	-6,2%	-11.4%	-34.2%

¹⁾ Q3 2022: adjusted for the negative one-off effect of the impairment in the segment Sempermed (Q3 2022: EBIT effect: EUR -51,8 million).

²⁾ Q4 and 2022: Adjusted for the one-off effect of the negative effect of the net impairments in the Sempermed segment (2022: effect on EBIT: EUR -10.8 million) and the one-off effect of the transaction costs (2022: effect on EBITDA and EBIT: EUR 8.4 million).



Key figures 2012-2022

Key performance figures											
in EUR m	2012	2013	2014 ¹⁾	2015 ¹⁾	2016 adj. ²⁾	2017 adj. ³⁾	2018 adj. ⁴⁾	2019 adj. ⁵⁾	2020 adj. ⁶⁾	2021	2022
Revenue	828.6	906.3	858.3	914,7	852.4	874.2	878.5	840.6	927.6	1 182.2	1 058.2
EBITDA	108.7	132.5	101,.	96,2	74.7	35.8	50.3	63.8	208.6	361.8	90.5
EBITDA margin	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%	30.6%	8.6%
EBIT	72.5	87.8	63.8	66,7	41.1	-0.8	15.4	28.2	171.4	315.0	25.8
EBIT margin	8.8%	9.7%	7.4%	7.3%	4,8%	-0.1%	1.7%	3.6%	18.5%	25.6%	2.4%
Earnings after tax	46.2	54.9	37,8	46,4	15,2	-43.9	-17.3	-0.2	121.9	247.5	-5.6
EPS, in EUR	2.25	2.65	1.85	2,26	0.74	-2.08	-1.06	-0.33	5.53	11.99	-0.27
Gross cash flow	85.6	116.2	89.9	55,7	48.1	32.2	37.4	46.70	193.7	323.4	30.5
Return on equity	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%	45.7%	-1.1%


Balance sheet key figures											
in EUR m	2012	2013	2014 ²⁾	2015 ²⁾	2016	2017	2018	2019	2020	2021	2022
Balance sheet total	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8	764.4	958.6	842.9
Equity	406.2	411.5	443.8	363.3	329.3	278.5	329.5	237.4	332.3	540.1	518.2
Equity ratio	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%	56.3%	61.5%
Investments in tangible and intangible assets	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4	56.4	50.1
Employees, at balance sheet date, FTEs	9 577	10 276	6 888	7 053	6 974	6 838	6 773	6 902	6 943	6 948	6 528

¹⁾ 2014 and 2015 restated. ²⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. ³⁾ 2017 adjusted for positive one-off effects from JV transaction of EUR 85m (EUR 65m for net profit) and negative one-off effects from impairment at Sempermed (EUR 26m adj. EBIT, EAT only), from restructuring expenses in France (EUR 11m), valuation adjustment in IT (EUR 4m EBITDA, EUR 3m EBIT) and expenses resulting from tax audit in Austria (EUR 5m, mainly for refund of energy supply charge). ⁴⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (EUR 4m for EBITDA, EUR 8m for EBIT and EAT) and for impairment of Sempermed of EUR 55m (adj. for EBIT and EAT only). ⁵⁾ FY 2019 adjusted for positive one-off effects of EUR 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of EUR 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). ⁶⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million); ⁷⁾ 2022 EBITDA & EBIT: as if no separation has taken place, segment view; balance sheet according to IFRS 5, with reclassifications



Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Overview price indices LFO-F-NWE / wire rod


Significant increase for raw material¹⁾ used in industrial segments

Price index LFO-F-NWE



— Fuel Oil 1% Sulphur NWE FOB Cargo

Price index wire rod



— Price index wire rod (Germany)

¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Product / market position / segment view, FY 2022

in EUR m

Semperit Group

	Industrial Sector				Medical Sector ⁴⁾
	Semperflex	Sempertrans	Semperform	Semperseal	Sempermed
Revenue	328.8 / 31% ¹⁾	151.9 / 14% ¹⁾	111.1 / 10% ¹⁾	142.1 / 13% ¹⁾	324.2 / 30% ¹⁾
EBITDA	82.2	19.7	15.1	8.3	-15.4
Employees	1,782 / 27% ³⁾	889 / 13% ³⁾	591 / 9% ³⁾	560 / 9% ³⁾	2,597 / 40% ³⁾

Products and market position

Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe
6 position globally



Conveyor belts

One of the leading suppliers of heavy-duty steel cord and textile conveyor belts



HSA* / SES**

Leading European manufacturers of moulded and extrusion products made of polymer and plastics (handrails, cable car rings, ski foils and Engineered Solutions)



Profiles / Rubber Sheeting

Leading European manufacturer of sealing profiles and elastomer sheeting (construction, packaging, machinery, HVAC, marine, electric systems)



Examination gloves

Among the top 15 glovemakers in the world



Surgical gloves

Among the leading companies in Europe




*Handrails, Special Applications
** Semperit Engineered Solutions

¹⁾ Revenue in % of Group revenue.
³⁾ Employees in % of Group employees.
Figures refer to segment view.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from supportive ownership structure with long-term commitment from B & C